About: Tolbutamide     Goto   Sponge   Distinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. (en)
http://linked.open...y/drugbank/dosage
http://linked.open...generalReferences
  • # Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19515014 (en)
http://linked.open...gy/drugbank/group
  • approved (en)
http://linked.open...drugbank/halfLife
  • Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas. (en)
http://linked.open...ugbank/indication
  • For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise. (en)
sameAs
Title
  • Tolbutamide (en)
adms:identifier
http://linked.open...mechanismOfAction
  • Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose. (en)
http://linked.open...drugbank/packager
http://linked.open...outeOfElimination
  • Unchanged drug and metabolites are eliminated in the urine and feces. Approximately 75-85% of a single orally administered dose is excreted in the urine principally as the 1-butyl-3-p-carboxyphenylsulfonylurea within 24 hours. (en)
http://linked.open.../drugbank/synonym
  • Tolbutamide (en)
  • Tolylsulfonylbutylurea (en)
  • 1-Butyl-3-(P-methylphenylsulfonyl)urea (en)
  • 1-Butyl-3-(P-tolylsulfonyl)urea (en)
  • 1-Butyl-3-tosylurea (en)
  • 1-P-Toluenesulfonyl-3-butylurea (en)
  • 3-(P-Tolyl-4-sulfonyl)-1-butylurea (en)
  • N-(4-Methylbenzenesulfonyl)-n'-butylurea (en)
  • N-(4-Methylphenylsulfonyl)-n'-butylurea (en)
  • N-(P-Methylbenzenesulfonyl)-n'-butylurea (en)
  • N-(Sulfonyl-P-methylbenzene)-n'-N-butylurea (en)
  • N-Butyl-N'-(p-tolylsulfonyl)urea (en)
  • N-Butyl-n'-(4-methylphenylsulfonyl)urea (en)
  • N-Butyl-n'-P-toluenesulfonylurea (en)
  • N-N-Butyl-n'-tosylurea (en)
  • Orinase (tn) (en)
  • Tolbutamida (en)
  • Tolbutamidum (en)
http://linked.open...drugbank/toxicity
  • Oral, mouse: LD<sub>50</sub> = 2600 mg/kg (en)
http://linked.open.../drug/hasAHFSCode
http://linked.open...nk/proteinBinding
  • Approximately 95% bound to plasma proteins. (en)
http://linked.open...ynthesisReference
  • Yan-Ping Chen, Pai-Ching Lin, "Tolbutamide Particle And Preparing Method Thereof And Method Of Reducing A Blood Glucose." U.S. Patent US20120121707, issued May 17, 2012. (en)
foaf:page
http://linked.open...ugbank/IUPAC-Name
http://linked.open...gy/drugbank/InChI
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...noisotopic-Weight
http://linked.open...y/drugbank/SMILES
http://linked.open.../Water-Solubility
http://linked.open...ogy/drugbank/logP
http://linked.open...ogy/drugbank/logS
http://linked.open...logy/drugbank/pKa
http://linked.open...l/drug/hasATCCode
http://linked.open...nd-Acceptor-Count
http://linked.open...-Bond-Donor-Count
http://linked.open...drugbank/InChIKey
http://linked.open...urface-Area--PSA-
http://linked.open...nk/Polarizability
http://linked.open...bank/Refractivity
http://linked.open...atable-Bond-Count
http://linked.open...ugbank/absorption
  • Readily absorbed following oral administration. Tolbutamide is detectable in plasma 30-60 minutes following oral administration of a single dose with peak plasma concentrations occurring within 3-5 hours. Absorption is unaltered if taken with food but is increased with high pH. (en)
http://linked.open.../affectedOrganism
  • Humans and other mammals (en)
http://linked.open...casRegistryNumber
  • 64-77-7 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...gbank/containedIn
http://linked.open...k/Bioavailability
http://linked.open...bank/Ghose-Filter
http://linked.open...nk/MDDR-Like-Rule
http://linked.open...ank/Melting-Point
http://linked.open...k/Number-of-Rings
http://linked.open...siological-Charge
http://linked.open...bank/Rule-of-Five
http://linked.open...tional-IUPAC-Name
http://linked.open...strongest-acidic-
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software